A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with Hypochondroplasia
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Vosoritide (Primary)
- Indications Hypochondroplasia
- Focus Registrational; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 19 Feb 2025 According to a BioMarin Pharmaceutical media release, this study remains on track to launch in 2027.
- 24 Apr 2024 According to a BioMarin Pharmaceutical media release, this study is expected to complete enrollment in the first half of 2025.
- 22 Feb 2024 According to a BioMarin Pharmaceutical media release, study is expected to begin mid-2024.